XM does not provide services to residents of the United States of America.
B
B

Biogen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Hargreaves Lansdown, Lagardere, SocGen, European Energy Exchange; updates Anglo American May 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1930 GMT on Wednesday: * * A consortium comprising CVC Advisers and the Abu Dhabi Investment Authority said it was considering a possible revised offer for Hargreaves Lansdown HRGV.L after the British investment platform's board rejected a buyout proposal it had made in A
B
D
H
L
N
S
A
G

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Biogen, Oaktree Capital Management Updates: Anglo American, Abu Dhabi National Oil Company May 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday: ** Anglo American AAL.L rejected a takeover proposal from BHP Group BHP.AX that valued the company at 29.34 pounds per share.
B
A
G

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio With Agreement To Acquire Human Immunology Biosciences

BRIEF-Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio With Agreement To Acquire Human Immunology Biosciences May 22 (Reuters) - Biogen Inc BIIB.O : BIOGEN BOLSTERS LATE-STAGE PIPELINE, EXPANDS IMMUNOLOGY PORTFOLIO WITH AGREEMENT TO ACQUIRE HUMAN IMMUNOLOGY BIOSCIENCES BIOGEN INC: BIOGEN WILL MAKE AN UPFRONT PAYMENT TO HI-BIO OF $1.15 BILLION.
B

Biogen in up to $1.8 bln deal as rare diseases take center stage

UPDATE 2-Biogen in up to $1.8 bln deal as rare diseases take center stage Adds details and background throughout May 22 (Reuters) - Biogen BIIB.O said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
B

Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal

Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal May 22 (Reuters) - Biogen BIIB.O said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments. Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.